The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients
- 1 January 1989
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 23 (1) , 8-14
- https://doi.org/10.1007/bf00258450
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelinesEuropean Journal of Cancer and Clinical Oncology, 1987
- Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemiasJournal of Medicinal Chemistry, 1987
- Effects of anthrapyrazole antineoplastic agents on lipid peroxidationBiochemical and Biophysical Research Communications, 1986
- In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles)Biochemical Pharmacology, 1985
- Role of metals in oxygen radical reactionsJournal of Free Radicals in Biology & Medicine, 1985
- Determination of cardiac output in the mouseZeitschrift für Die Gesamte Experimentelle Medizin, 1979
- 5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracyclineJournal of Medicinal Chemistry, 1979
- Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor ResponseScience, 1977
- Chronic toxicity of adriamycin: A new antineoplastic antibioticToxicology and Applied Pharmacology, 1972
- Adriamycin: Toxicity dataCellular and Molecular Life Sciences, 1970